Concepedia

Deepak Assudani

DA

Statistics

Publications

15

Citations

1.2K

H-Index

12

Active since

2008

Affiliations

UCB Pharma (United States)(Current)

UCB Pharma (United Kingdom)

Inserm

Icahn School of Medicine at Mount Sinai

Institut Pierre Louis d‘Épidémiologie et de Santé Publique

Deepak Assudani is an author at UCB Pharma (United States) specializing in medicine, clinical trials, and inflammatory arthritis.

Top concepts

Publications per year

2008–2022

15

Publications

15

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

Rupal Ramakrishnan, Deepak Assudani, Srinivas Nagaraj et al. · Journal of Clinical Investigation · 2010 · 456 citations · Full text

, , +14

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

Joseph F. Merola, Robert Landewé, Iain B. McInnes et al. · The Lancet · 2022 · 149 citations · Full text

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)

Iain B. McInnes, Akihiko Asahina, Laura C. Coates et al. · The Lancet · 2022 · 146 citations · Full text

Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial

Christopher T. Ritchlin, Arthur Kavanaugh, Joseph F. Merola et al. · The Lancet · 2020 · 140 citations · Full text

, , +9

Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study

Stanley Cohen, A. Alonso-Ruiz, Piotr Adrian Klimiuk et al. · Annals of the Rheumatic Diseases · 2018 · 112 citations · Full text

1–5 of 15